Sophia Lugo
Chief Executive Officer, Chairman & Co-Founder Radar Therapeutics
Sophia Lugo is Chief Executive Officer, chairman and co-founder at Radar Therapeutics, which develops genetic medicines that turn on only in the right cell, at the right time, with exquisite specificity. Before Radar, Sophia held strategy and product roles at BGI Genomics’ Health Division and Ventures Incubator, the Boston Consulting Group, the U.S. Surgeon General’s Office, and the Bill & Melinda Gates Foundation, where she led COVAX planning efforts and tracked communications and real-time strategic responses for the COVID vaccine rollout.
Seminars
Being able to design and develop an mRNA drug from concept into an effective drug product can be a challenge, with new emerging technologies and that require validation and regulatory approval. However, without this, there is limited progress to expand mRNA potential.
This workshop will explore the latest innovations on the horizon, bringing together key thought-leaders to share their insights and experience on the future directions and potential of mRNA by setting a roadmap from discovery to market and ensuring better outcomes for patients.
This workshop will address:
- Where are the current gaps in RNA innovation that can be filled?
- What roadmap and endpoints are required to transition your platform from discovery to market?
- What funding opportunities are there for new innovations and to ensure they can be clinically validated?
Case Studies Include:
- Pioneering Selectively Activated, Precise In Vivo mRNA Therapeutics
- Engineering Novel Circular RNA Therapeutics
- Developing Broadly-Protective Vaccines on PopVax’s mRNA-LNP Platform Using Machine Learning-Enabled Computational Immunogen Design
